Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb tells Proactive the Florida-based biotech is 'delivering on its promises.' Emalfarb says it saw a busy first quarter where the company stepped up in the global fight against the coronavirus pandemic.
Emalfarb says among its recent achievements, the company is working with worldwide research partners to leverage its proprietary C1 technology to express an increasing number of potential coronavirus vaccines and antibody candidates.
